Navigation Links
AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures

WOBURN, Mass., June 3 /PRNewswire/ -- AdvanDx today announced the FDA 510(k) submission of Yeast Traffic Light PNA FISH(TM) for detection of Candida yeast species from positive blood cultures. Yeast Traffic Light(TM) is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics platform that provides rapid identification of bloodstream pathogens in hours instead of days. Candidemia, a bloodstream infection caused by Candida species is one of the most serious hospital acquired infections, afflicting over 24,000 patients in the U.S. every year. Immunocompromised transplantation, oncology and AIDS patients are especially at risk for contracting the infection with mortality rates as high as 50%.(1) While identification of the infecting Candida species is used to guide effective antifungal therapy, conventional laboratory methods can take up to 5 days or longer. Yeast Traffic Light(TM) will for the first time enable laboratories to rapidly detect, in a single test, up to five Candida species directly from positive blood cultures including C. albicans and C. parapsilosis, C. tropialis, and C. glabrata and C. krusei in hours instead of days. The rapid results should enable clinicians to provide early, effective and appropriate antifungal therapy for patients with candidemia.

A recent study by Della-Latta et al. presented at the 2008 ECCMID meeting in Barcelona, Spain demonstrated that rapid identification of Candida species using PNA FISH can significantly impact antifungal selection and care for patients with Candidemia. In the study, rapid identification of C. albicans led to a switch to the antifungal drug fluconazole for 70% of the patients that had been on caspofungin, a newer, more broad-spectrum but more expensive antifungal drug. At the same time, rapid identification of C. glabrata, a Candida species with high levels of resistance to fluconazole, led to an 81% switch to caspofungin for those patients that had otherwise been given fluconazole. Based on the study results, the authors concluded that the PNA FISH test "can impact the appropriate selection of the most effective antifungal therapy, thereby making it a clinically relevant diagnostic assay." (2)

"The Yeast Traffic Light PNA FISH test demonstrates AdvanDx's commitment to developing cutting-edge molecular diagnostic products that provide fast results for these serious infections," said Thais T. Johansen, President and CEO of AdvanDx. "The test will ultimately enable clinicians to provide more appropriate care, improve antifungal selection and hopefully improve outcomes for their patients," Johansen concluded.

About Bloodstream Infections

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The infection is detected when a culture of the patient's blood, i.e. a blood culture, turns positive with bacteria and yeast. Rapid and accurate identification of the specific infecting pathogen is crucial to ensure early and appropriate therapy and save patient lives.


PNA FISH is an easy-to-use and highly sensitive and specific fluorescence in situ hybridization (FISH) assay that uses PNA (peptide nucleic acid) probes to target species specific ribosomal RNA (rRNA) in bacteria and yeast. PNA FISH tests enable microbiology labs to provide rapid and accurate identification of bloodstream pathogens directly from positive blood cultures in hours instead of days. Clinical studies show that rapid identification of bloodstream pathogens using PNA FISH tests leads to more appropriate patient therapy that saves lives and reduces unnecessary antibiotic use, patient length of stay and hospital costs.

About AdvanDx

AdvanDx is the world's leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit


Company Contact: Media Inquiries:

Joen T. Johansen Joe Romano

Director of Marketing Partner

AdvanDx HighGround, Inc.

+1-339-227-4052 +1-781-939-5800 Ext 208


1. Spellberg et al. Current Treatment Strategies for Disseminated

Candidiasis. Clin. Infec. Dis. 42: 244-251. 2005

2. Della-Latta et al. Impact of Rapid Identification of C. albicans and

C. glabrata Directly from Blood Cultures using PNA FISH Technology on

Selection of Antifungal Therapy. Poster 1382. ECCMID 2008.

Barcelona, Spain.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
9. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. (NASDAQ: ... on gastrointestinal and cardio-renal diseases, today announced that ... tenapanor, will be presented at the 2015 American ... will include measures of sustained response in IBS-C ... placebo-controlled, randomized Phase 2 trial. The meeting will ...
(Date:10/8/2015)... 2015  Trovagene, Inc., (NASDAQ:   TROV) a ... presentation of results from a field experience analysis ... SM (PCM) platform to accurately identify mutational ... determine appropriate therapy for patients. Mark Erlander ... delivering the results today in an oral presentation ...
(Date:10/8/2015)... 2015  Following months of investigation, Ross Feller Casey ... alleging that the anticoagulant Xarelto,s recommended dosage doesn,t work for ... Philadelphia on behalf of a ... the drug didn,t work as the manufacturer suggested. Ross ... shortly on behalf of clients from across the country with ...
Breaking Medicine Technology:
... CLARA, Calif., Oct. 7, 2011 ProteinSimple today ... and field service support for its biologics products ... product lines are included in this expanded support ... Micro-Flow Imaging systems. The biologics market ...
... (Nasdaq: CPHD ) today announced that it will ... 30, 2011, on Thursday, October 20, 2011, after the close ... management presentation at 2 p.m. Pacific Time on Thursday, October ... webcast, please visit Cepheid,s website at at ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... The sixth annual cost of cybercrime study the Ponemon Institute released this ... The New York Times broke down some of those numbers in this article ... the companies surveyed, it only proves that regular threat assessments, penetration testing and emergency ...
(Date:10/10/2015)... ... ... Story Chaser is a one-of-a-kind app that makes reading fun while helping children ... words drop down and users tap the corresponding word. By answering correctly player earn ... making it a more engaging game. Users can use what are called Reading Powers ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, ... Place To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The ... up with a celebratory gala on October 1st. , Many of the features ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... the Pacific Associate Dean for Graduate Medical Education J. Michael Finley, DO, as ... Award. Finley was selected for his impact on graduate medical education opportunities for ...
Breaking Medicine News(10 mins):
... CardioCareLive, the world,s largest live online cardiology congress ... Medicine, today announced three new complimentary Continuing Medical ... days on Tuesday June 28th and Wednesday June ... and internal medicine and family care physicians in ...
... latest episode in the American Chemical Society,s (ACS) ... focuses on new blood test that can quickly ... bacterium that,s become a global threat, significantly improving ... Staphylococcus aureus, or simply MRSA. The podcast explains ...
... 24 (HealthDay News) -- Rain-making bacteria may shed some ... the Earth,s precipitation cycle, new research shows. ... meeting of the American Society for Microbiology in New ... of hailstones, suggesting that airborne microorganisms may trigger precipitation, ...
... knowledge of tuberculosisas well as in the practices, programs ... with human immunodeficiency virus (HIV)the spread of multidrug-resistant (MDR) ... community. Research in the June issue of The ... use of 18F-FDG positron emission tomography (PET) scans can ...
... MA Electronic medical records (EMRs) have been in use ... utilization in recent years, due in part to research supporting ... become a standard in medical care, there is a need ... be refined. A group of researchers from Brigham and Women,s ...
... you may want to think twice before shooting hundreds of ... study from MIT neuroscientists shows that the most memorable photos ... and human-scale objects. Landscapes? They may be beautiful, but they ... are not the same," says MIT graduate student Phillip Isola, ...
Cached Medicine News:
The MACS VA_500 (variable atmosphere) is primarily for the study and isolation of microaerophilic organisms,including Campylobacter spp,Helicobacter pylori and other similarly fastdious organisms....
... an electrical power supply, MERKUR offers a broad ... a gas spring for ease of operation. For ... a foot pedal hydraulic system. Thanks to its ... anytime in a highly mobile and flexible manner. ...
... The operating table MARS Enduro ... examinations or interventions are required before, ... Due to the motorised longitudinal adjustment ... provides optimum working conditions in examination, ...
... Exclusive, 210° Top Rotation provides uncommon ... surgery. The Hercules 6700B eliminates any ... head-end procedures, while providing ample leg ... sit during procedures. Removable back and ...
Medicine Products: